CompanyCOCPNasdaqBothell, WA

Cocrystal Pharma, Inc.

Cocrystal Pharma discovers and develops antiviral therapeutics targeting noroviruses, influenza viruses, coronaviruses including SARS-CoV-2, and hepatitis C viruses using structure-based drug design.

Stories only

SEC EDGAR ClinicalTrials.gov cocrystalpharma.com

8-KSep 14Latest SEC filing, period to Sep 8

Sep 14Latest story

September 2026

Cocrystal Pharma completes dosing in norovirus challenge study of CDI-988

Sep 9Clinical readoutCDI-988 Cocrystal Pharma, Inc.

August 2026

Cocrystal Pharma posts Phase 1 results for CDI-988, an oral SARS-CoV-2 antiviral candidate

Aug 19Trial updateCDI-988 Cocrystal Pharma, Inc.

Cocrystal Pharma adds Carol Brosgart, MD to board of directors

Aug 18PeopleCocrystal Pharma, Inc.

Cocrystal Pharma confirms $5 million OPKO Health private placement in 8-K filing

Aug 3Clinical readoutCDI-988 Cocrystal Pharma, Inc.